About GHK-Cu MD — Independent Research Index for the Copper Tripeptide

About GHK-Cu MD

GHK-Cu MD is a medical-literature desk: it publishes summaries of the peer-reviewed research on GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) Complex) for readers who want the indexed record. It runs no clinic and keeps no clinical staff; it gives no medical advice and recommends no dose; and it makes, stocks, and sells nothing. The work is one reader indexing published papers and reporting them with their citations.

The 'MD' in the name designates a medical-literature desk — the register of a reference reader who indexes primary papers, not a treating physician. This site organizes the GHK-Cu evidence base in the way a medical librarian would: by mechanism, by application domain, by study design, and by the strength of the evidence. The editorial voice is clinical-but-approachable — precise where the data is precise, honest where it is not, and consistently cited.

What this site covers

GHK-Cu has accumulated more than 300 peer-reviewed publications since Loren Pickart first isolated it from human albumin in 1973. The literature spans wound healing, collagen synthesis, hair follicle biology, gene modulation, neuroprotection, antioxidant defense, and gut mucosal repair — a scope that makes a single, organized reference resource useful.

This site indexes the primary research findings, translates quantitative data into plain language, maps the open questions, and maintains the citation record. Every statistic is sourced. Every study description names the species, dose, route, and outcome. The regulatory status of GHK-Cu (not FDA-approved for any therapeutic indication; approved as a cosmetic ingredient under the INCI system as Copper Tripeptide-1) is stated plainly throughout.

Pages are organized by application domain: the GHK-Cu mechanism of action and gene-modulation evidence on the Research page; the copper peptide hair growth research on the Hair Growth page; copper peptide for skin repair on the Skin Research page; and the full GHK-Cu dosage in preclinical studies on the Dosage page. The frequently asked questions address the 22 most common questions drawn from peer-reviewed literature, patient forums, and published review sources.

Editorial standards

Every quantitative claim on this site is cited to its source. The format is consistent: species, dose, route, outcome, and citation number. No claim is written without a published source in our research corpus. Invented citations are an editorial failure this site treats as a hard rule violation.

The voice is calibrated to what the literature actually shows — not what would be most persuasive. When the evidence base is strong (thirty-plus wound-healing publications showing consistent findings), the site says so. When the evidence base is thin (injectable GHK-Cu in humans: no completed clinical trials), the site names the gap rather than burying it.

The site does not accept advertising. It does not have commercial relationships with suppliers, compounders, or vendors of any GHK-Cu product. It does not link to vendors. It does not recommend products.